Last updated: February 23, 2026
What is NDC 83324-0008?
NDC 83324-0008 identifies a specific formulation of the drug Emicizumab (Hemlibra). It is indicated for prophylaxis in patients with hemophilia A with inhibitors and is marketed by Roche.
Market Size and Demand
Hemlibra (emicizumab) continues to gain acceptance as a preferred prophylactic treatment for hemophilia A. The global hemophilia market was valued at approximately $10.5 billion in 2022[1]. The subset of patients with inhibitors, estimated at 20% of hemophilia A patients, represents a specialized but significant market segment.
Estimated Market Penetration:
- Hemlibra accounts for around 35% of prophylactic treatments in hemophilia A.
- Growth rate for hemophilia treatments is projected at 6.5% CAGR through 2027[2].
Patient Population:
- Approximate global hemophilia A population: 200,000.
- Patients with inhibitors: 40,000.
- Estimated annual demand for Hemlibra: 10,000 to 15,000 patients.
Product Pricing and Revenue Potential
Current Wholesale Acquisition Cost (WAC):
- The average annual cost per patient ranges from $420,000 to $480,000[3].
Pricing Trends:
- Roche has maintained pricing stability amid increasing competition.
- Proposed price increases may target new formulations or flexible dosing options, potentially adding 5-8% annually.
| Revenue Projections: |
Year |
Estimated Units |
Price per Unit |
Total Revenue (USD) |
| 2023 |
10,000 |
$450,000 |
$4.5 billion |
| 2024 |
12,000 |
$470,000 |
$5.64 billion |
| 2025 |
14,000 |
$490,000 |
$6.86 billion |
| 2026 |
15,000 |
$510,000 |
$7.65 billion |
Assumptions:
- Growing adoption rate.
- Stable pricing with slight increase.
- No major market disruptions or generic competition within forecast period.
Competitive Landscape
- Adynovate (higher dosage options): Focused on prevention, priced similar to Hemlibra.
- BPL-001 (biosimilar products): Limited availability; generic versions expected within 5-7 years.
- Gene therapy (luxturna, et al.): Not directly competing but may influence long-term demand.
Regulatory and Reimbursement Factors
- FDA approval in 2017.
- Reimbursement largely secured through insurance and government programs in major markets.
- Pricing negotiation pressures are increasing, especially in Europe and emerging markets.
Key Challenges and Risks
- Patent expirations forecasted around 2030, risking generic entry.
- Market saturation could slow growth.
- Pricing pressures with healthcare payers.
- Competition from emerging gene therapies.
Price Projections and Outlook
- Likely stabilization around $450,000-$500,000 per year per patient.
- Incremental increases driven by manufacturing costs, inflation, and new DTC strategies.
- If biosimilar competitors emerge by 2028, prices could decline 20-30%.
Key Takeaways
- The global hemophilia A market offers a sizable, sustained demand for Hemlibra.
- Market growth forecasted at approximately 6.5% CAGR through 2027.
- Current pricing remains stable but faces potential downward pressure post-patent expiry.
- Revenue forecasts suggest the drug could generate over $7 billion annually in peak years.
- Competitive pressure and regulatory shifts are key risks influencing long-term price stability.
FAQs
1. How does the price of NDC 83324-0008 compare to other hemophilia treatments?
Hemlibra's annual treatment cost is roughly comparable or slightly higher than traditional factor VIII replacements but offers convenience by reducing infusion frequency, which may justify premium pricing.
2. What factors could influence future price changes for Hemlibra?
Pricing adjustments depend on market competition, patent status, regulatory policies, and negotiations with payers. The entry of biosimilars could significantly lower prices after 2028.
3. What is the expected timeline for biosimilar competition?
Biosimilars are projected to enter the market within 5-7 years post-patent expiry, likely between 2028 and 2030.
4. How effective are current reimbursement policies for Hemlibra?
Reimbursement is generally favorable in developed markets, with coverage for most insurance plans and government healthcare programs, supporting current pricing strategies.
5. Are there any upcoming regulatory or policy changes that could impact market size?
Regulatory agencies may implement stricter pricing controls or value-based reimbursement policies, potentially constraining prices and influencing demand.
References
[1] Grand View Research. (2023). Hemophilia treatment market size, share & trends analysis. https://www.grandviewresearch.com
[2] MarketsandMarkets. (2022). Hemophilia market forecast and analysis. https://www.marketsandmarkets.com
[3] IQVIA Institute. (2022). The Global Use of Medicines in 2022 and Outlook to 2026. https://www.iqviainstitute.org
